Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO-BM biomarker add-on study to FIGARO-DKD
jRCT2071210061Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Open-label trial of finerenone in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bayer. Primary endpoint: Change in plasma biomarker levels between 4 and 36 months of treatment. Started Aug 2021; status: completed.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2071210061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210061.